Alkermes plc Stock News

Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment.

—  Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET — DUBLIN , Oct. 10, 2023  /PRNewswire/ -- Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS)

Alkermes (ALKS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALKS broke through the 50-day moving average, which suggests a short

DUBLIN , Sept. 5, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.

Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.

Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. TEVA, relating to Vivit

Alkermes to split neuroscience and oncology divisions; strong growth with drug Lybalvi highlighted. Financials show robust growth; concerns include a projected 2024 revenue dip and Vivitrol litigation

Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi

Alkermes plc (NASDAQ:ALKS ) Q2 2023 Earnings Conference Call July 26, 2023 8:00 AM ET Company Participants Sandra Coombs – Senior Vice President-Corporate Affairs and Investor Relations Iain Brown �

Alkermes (ALKS) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.06 per share a year ago.

Here is how Alkermes (ALKS) and Haemonetics (HAE) have performed compared to their sector so far this year.

Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall

Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.

Here is how Alkermes (ALKS) and Masimo (MASI) have performed compared to their sector so far this year.

ALKS, $31.48, Market Capitalization: $5.